Kessous R, Wissing MD, Laskov I, et al. - Since there is a lack of guidelines for the treatment of tubo‐ovarian cancer patients beyond third line, therefore, researchers undertook this cohort analysis to assess the impact of response in each line on patient's outcome and to explore variables predictive of response for the additional line of chemotherapy. Participants were patients suffering from advanced high‐grade ovarian cancer. This study involved 238 patients who received up to 10 lines of chemotherapy. A decline in response rates was evident with each additional line and by line 5, the majority of patients (61%) became refractory and only 16% showed any type of response (complete 4% or partial 12%). By line 2, if a patient had partial disease, stable disease or progressive disease did not have an impact on the overall survival. Findings revealed that the major clinical factor that was identified as a predictor of the beneficial impact of another line of treatment in patients with ovarian cancer was time interval from the previous line of chemotherapy.